Across TCGA pan-cancer cohorts, SMIM5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SMIM5 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SMIM5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMIM5 expression acts as an unfavorable survival marker.

LIHC and BRCA are the cancer types where SMIM5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.061	0.783	<.001	12	view →
BRCA	OS	Median	All	0.136	0.578	.023	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SMIM5 tumor-vs-normal RNA expression · all SMIM5 data types